Based on the verification of in vitro activation of switchable CAR‐T and in vivo tumor targeting capabilities of gelatinase‐responsive NPs, we then assessed the in vivo antitumor effect in mice bearing HER2 high‐expressed MKN45 xenograft tumor model (Figure 3b). The gene discussed is ERBB2; the disease is neoplasm.